| Literature DB >> 27588018 |
Chang Liu1, Xin Wang2, Yuhuang Chen2, Huijing Hao2, Xu Li2, Junrong Liang2, Ran Duan2, Chuchu Li1, Jing Zhang2, Shihe Shao3, Huaiqi Jing2.
Abstract
In many gram negative bacilli, AmpD plays a key role in both cell well-recycling pathway and β-lactamase regulation, inactivation of the ampD causes the accumulation of 1,6-anhydromuropeptides, and results in the ampC overproduction. In Yersinia enterocolitica, the regulation of ampC expression may also rely on the ampR-ampC system, the role of AmpD in this species is still unknown. In this study, three AmpD homologs (AmpD1, AmpD2, and AmpD3) have been identified in complete sequence of strain Y. enterocolitica subsp. palearctica 105.5R(r). To understand the role of three AmpD homologs, several mutant strains were constructed and analyzed where a rare ampC regulation mechanism was observed: low-effective ampD2 and ampD3 cooperate with the high-effective ampD1 in the three levels regulation of ampC expression. Enterobacteriaceae was used to be supposed to regulate ampC expression by two steps, three steps regulation was only observed in Pseudomonas aeruginosa. In this study, we first reported that Enterobacteriaceae Y. enterocolitica can also possess a three steps stepwise regulation mechanism, regulating the ampC expression precisely.Entities:
Keywords: AmpC β-lactamase; AmpD; Yersinia enterocolitica; antimicrobial resistance; synergy effect
Year: 2016 PMID: 27588018 PMCID: PMC4988969 DOI: 10.3389/fmicb.2016.01282
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Strains and plasmids used in this study.
| 105.5R(r) | Wild type; completely sequenced | Wang et al., |
| YEΔD1 | 105.5R(r) Δ | This work |
| YEΔD2 | 105.5R(r) Δ | This work |
| YEΔD3 | 105.5R(r) Δ | This work |
| YEΔD1D2 | 105.5R(r) Δ | This work |
| YEΔD1D3 | 105.5R(r) Δ | This work |
| YEΔD2D3 | 105.5R(r) Δ | This work |
| YEΔD1D2D3 | 105.5R(r) Δ | This work |
| 105.5R(r)- | 105.5R(r) containing plasmid pBBR- | This work |
| YEΔD1- | YEΔD1 containing plasmid pBBR- | This work |
| YEΔD2- | YEΔD2 containing plasmid pBBR- | This work |
| YEΔD3- | YEΔD3 containing plasmid pBBR- | This work |
| YEΔD1D2- | YEΔD1D2 containing plasmid pBBR- | This work |
| YEΔD1D3- | YEΔD1D3 containing plasmid pBBR- | This work |
| YEΔD2D3- | YEΔD2D3 containing plasmid pBBR- | This work |
| YEΔD1D2D3- | YEΔD1D2D3 containing plasmid pBBR- | This work |
| DH5α | F- | Invitrogen |
| S17 λpir | λ-pir R6K( | Simon et al., |
| pDS132 | CmR; Conditionally replicating vector; R6K origin, | Philippe et al., |
| pDSD1 | CmR; pDS132 containing 5′ and 3′ flanking sequence of amp | This work |
| pDSD2 | CmR; pDS132 containing 5′ and 3′ flanking sequence of amp | This work |
| pDSD3 | CmR; pDS132 containing 5′ and 3′ flanking sequence of amp | This work |
| pBBRLux | CmR; Luminescence without promoter (or contains a promoterless | Zhou et al., |
| pLUX | CmR; pBBRlux containing 250 bp 5′ flanking sequence of | This work |
| pSRKTcD1 | TcR; pSRKTc containing 105.5R(r) | This work |
| pSRKTcD2 | TcR; pSRKTc containing 105.5R(r) | This work |
| pSRKTcD3 | TcR; pSRKTc containing 105.5R(r) | This work |
Primers used in this work.
| pΔ | GAGGTACCGCATGGCCTGTTTCAGCATAGTTGC | 952 | |
| pΔ | ACAAAGTGACAAACTATACGTTACCTAAGCCCCCTAACCT | ||
| pΔ | AGGTTAGGGGGCTTAGGTAACGTATAGTTTGTCACTTTGT | 945 | |
| pΔ | GAATTCCCGGGAGGCACCATAAATAGTCAGTAA | ||
| pΔ | GAGGTACCGCATGTACAAGCATTGGGTGAAGAA | 975 | |
| pΔ | TTAAATAACTTTTACCGCGCAAGCACAGTTATAGTGAACC | ||
| pΔ | GGTTCACTATAACTGTGCTTGCGCGGTAAAAGTTATTTAA | 992 | |
| pΔ | GAATTCCCGGGAGGTAACTGACCTGACCGTTCC | ||
| pΔ | GAGGTACCGCATGTTTATCGACACTCACAACTA | 954 | |
| pΔ | TGGCGGCGCTGTATCTAGTCTAATGTTATTTATTGAGGAT | ||
| pΔ | ATCCTCAATAAATAACATTAGACTAGATACAGCGCCGCCA | 945 | |
| pΔ | GAATTCCCGGGAGGTATCAGCCAATCACCAATG | ||
| pP | C | 384 | |
| pP | C | ||
| pC | C | 576 | |
| pC | C | ||
| pC | C | 852 | |
| pC | C | ||
| pC | C | 777 | |
| pC | C |
Restriction enzyme recognition sites are underlined.
Figure 1Amino acid sequence alignment of AmpD homologs of different Gram-negative bacteria using ClustalW. AmpD-E.col (E. coli K-12 accession no. AAC73221), AmpD-C.fre (C. freundii OS60 accession no. Z14002), AmpD-E.clo (E. cloacae accession no. CAA78391), AmpD-P.aer (P. aeruginosa PAO1 accession no. NP_253211), AmpDh2-P.aer (P. aeruginosa PAO1 accession no. NP_254172), AmpDh3-P.aer (P. aeruginosa PAO1 accession no. NP_249498), AmpD1-Y.ent (Y. enterocolitica accession no. WP_005156822), AmpD2-Y.ent (Y. enterocolitica 105.5R accession no. WP_005164953) and AmpD3-Y.ent (Y. enterocolitica 105.5R accession no. WP_013649890) are shown. Asterisk, colons, and periods represent identical, conserved, and semi-conserved residues, respectively. The conserved and essential amino acids for AmpD activity are indicated in bold.
Figure 2Amino acid sequence phylogenetic analysis of AmpD homologs from different Gram-negative bacteria. Y. enterocolitica AmpD1 belong to the branch A with the other “traditional” AmpD, Y. enterocolitica AmpD2 and AmpD3 belong to the second branch with P. aeruginosa AmpDh2 and AmpDh3 discovered recently.
Figure 3Induction assay by monitor the . Then the activity of ampC promoter of 105.5R(r) and its seven derived mutants were tested (B), the strains were grown in the 40 mg/L Cefoxitin for 1 h. Error bars indicate standard deviations for triplicate experiments.
Figure 4Three AmpD homologs cooperate to regulate the . (A) Inactivation of AmpD homologs causes the elevation on β-lactamase activity in variant degree. (B) In complementation assay, hyperproduction of single AmpD1 (pSRKTcD1) and AmpD2 (pSRKTcD2) in YEΔD1D2D3 will reduce the β-lactamase activity into wild-type strain levels, however, single AmpD3 (pSRKTcD3) do not possess full capacity as AmpD1 and AmpD3. This data are the average of the measurements made in triplicate, the error bars indicate standard deviations.
MICs of antibiotics for strain 105.5R(r) and .
| AMP | 32 | 32 | 32 | 32 | 32 | 64 | 32 | 64 |
| TIC | 1 | 4 | 2 | 1 | 4 | 4 | 2 | 4 |
| PIP | 2 | 16 | 4 | 2 | 16 | 16 | 4 | 16 |
| SAM | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| TZP | 1 | 4 | 2 | 1 | 4 | 4 | 2 | 4 |
| CFZ | 128 | 512 | 128 | 256 | 512 | 512 | 256 | 512 |
| CAZ | 0.25 | 1 | 0.5 | 0.25 | 1 | 2 | 0.25 | 2 |
| FEP | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| CRO | ≤ 0.125 | 0.25 | 0.25 | 0.25 | 0.5 | 0.5 | 0.25 | 0.5 |
| ATM | ≤ 0.125 | 0.5 | ≤ 0.125 | ≤ 0.125 | 0.5 | 1 | 0.25 | 1 |
| CTT | 2 | 4 | 2 | 2 | 4 | 4 | 4 | 4 |
| FOX | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| IPM | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| MEM | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| CIP | ≤ 0.03 | ≤ 0.03 | ≤ 0.03 | ≤ 0.03 | ≤ 0.03 | ≤ 0.03 | ≤ 0.03 | ≤ 0.03 |
AMP, Ampicillin; TIC, Ticarcillin; PIP, Piperacillin; SAM, Ampicillin-sulbactam; TZP, Piperacillin-tazobactam; CFZ, Cefazolin; CAZ, Ceftazidime; FEP, Cefepime; CRO, Ceftriaxone; ATM, Aztreonam; CTT, Cefotetan; FOX, Cefoxitin; IPM, Imipenem; MEM, Meropenem; CIP, Ciprofloxacin.
MIC was determined in triplicate by standard two-fold serial broth microdilution method, all measurements were performed in triplicate.